News Archive

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–LumaCyte, an advanced bioanalytical instrumentation company specializing in vaccine and cell and gene therapy bioprocess, production, and R&D analytical capabilities, announces its expansion into Europe with the establishment of LumaCyte, B.V. in The Netherlands. LumaCyte has experienced a rapid increase in global demand for Radiance®, it’s label-free single cell analysis instrument, with a large portion of that demand coming from Europe. In the fall of 2019, LumaCyte reported that it was strengthening its infrastructure to support a growing customer base, with strong efforts being placed on servicing the expansive European market. The company has expanded its US headquarters, significantly increasing manufacturing and laboratory footprints, as well as completed the rigorous EU specific regulatory CE mark certification, indicating Radiance® conformity with EEA health and safety standards, which is a prerequisite for its instrument sale and use.

Orgenesis Inc (NASDAQ:ORGS) announced a collaboration with Johns Hopkins University to utilize its point-of-care platform to develop and supply gene therapies and technologies. 

The company’s POCare cell therapy platform is designed to advance the development of Advanced Therapy Medicinal Products — medicines based on genes, tissues or cells — through collaborations and in-licensing with other companies. 

CEO Vered Caplan is confident in the pedigree and resources of the Baltimore research university. 

BALTIMORE, February 18, 2020 (Newswire.com) – Over 40 million patient records were breached in 2019, according to new data released today in the Protenus Breach Barometer®. Published by Protenus, a healthcare compliance analytics platform that protects patient data for the nation’s leading health systems, the Breach Barometer is the industry’s definitive source for health data breach reporting.  

Two commercial real estate firms with a significant presence in the marketing of life sciences properties have issued reports over the past 12 months that illustrate the growth in industry employment in recent years.

One life sciences segment, “Research and Development in Biotechnology” (NAICS code 541714), has largely driven that growth, with its number of jobs more than doubling over the past decade, to 204,800 as of 2019, according to the U.S. Bureau of Labor Statistics (BLS) data cited by Cushman & Wakefield in “Life Sciences 2020: The Future Is Here,” a report released February 6. Between 2010 and 2019, biotech R&D employment grew 5.1%, compared with 1.6% for total employment. Most of the increase, more than 70,000 jobs, occurred between 2013 and 2019.

Pete Briskman, an Executive Managing Director with JLL, leads the Tenant Advisory and brokerage business for JLL in Maryland, sits down with BioTalk Host Rich Bendis to talk his role with JLL, his focus on Life Sciences, and vision of the BioHealth Capital Region

Pete Briskman works with many of the regions’ most exciting and fastest growing Life Science Companies assisting them with their real estate and site selection strategies for Headquarter transactions, relocations, build-to-suits, renewals, expansions, and consolidations. Pete and his team bring proprietary tools to help organizations make informed decisions around the size and scale of their operation, assessment of labor, modeling and programming of occupancy, approach to optimizing business and economic incentives, and very unique real estate market intelligence that can be communicated via our proprietary geo-spatial market intelligence platform.  He is the recipient of GWCAR’s Commercial Leasing Broker of the Year and has been recognized with GWCAR Office Leasing Transactions of the Year for multiple clients.

SANTA MONICA, Calif.–(BUSINESS WIRE)–Feb. 10, 2020– Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

FREDERICK, Md.–(BUSINESS WIRE)–The Maryland Tech Council (MTC) announced today it has expanded its offices to Frederick to broaden its reach throughout the State of Maryland and to meet the growing needs of its members. The satellite office will be located at 12 West Church Street. Additionally, MTC is planning a move of its Montgomery County satellite office to the Universities at Shady Grove (USG) in Rockville. MTC will continue to utilize its satellite offices in Annapolis and other key life science and tech hubs throughout Maryland.

HHS on Monday launched a new program to spur development and commercialization of technologies that would help the U.S. respond to health security threats and disasters.

The Foundry for American Biotechnology, a public-private partnership, will be jointly managed by the department’s Office of the Assistant Secretary for Preparedness and Response—or ASPR—and the New Hampshire technology firm Deka Research and Development Corp.

Feb. 10, 2020 — Linda Larrimore has been getting chemotherapy every other week for 6 years to treat and manage colon cancer.

The chemotherapy is keeping her health stable, so it’s well worth it to the mother and grandmother to regularly get the treatment. Usually, she spends the 4½ hours every other week reading, watching TV, or chatting.

Image: https://www.webmd.com

New Enterprise Associates Partner Sara Nayeem sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York.

The venture capital fund, which has a cumulative committed capital of $20 billion, focuses on investing in across all verticals in healthcare and in technology.

Image: https://www.proactiveinvestors.com